Experimental Approaches to the Development of Inactivated Poliovirus Vaccine Based on Sabin Strains
https://doi.org/10.31631/2073-3046-2016-15-4-59-64
Abstract
The results of development of experimental series of inactivated poliovirus vaccine based on Sabin strains (s-IPV) using conventional modern techniques are presented. Comparative analysis of immunogenicity of the experimental s-IPV and commercial IPV prepared from «wild» poliovirus strains (Imovax, Sanofi Pasteur S.A., France) using several models of laboratory animals showed their identity regarding Sabin and «wild» strains. Original method (an ELISA using specific chicken egg yolk antibodies of class Y-IgY) for quantitative determination of D-antigen in elaboration of vaccine formulation has been developed and protected by patent; conventional control methods in accordance with the WHO and European Pharmacopoeia requirements have been adopted. Finally, at experimental level it was shown that basic characteristics of the s-IPV are comparable with those of commercial IPV prepared from «wild» poliovirus strains
About the Authors
A. P. Ivanov
ФГУП «Предприятие по производству бактерийных и вирусных препаратов Института полиомиелита и вирусных энцефалитов им. М.П. Чумакова
Russian Federation
Russian Federation
T. D. Klebleeva
ФГУП «Предприятие по производству бактерийных и вирусных препаратов Института полиомиелита и вирусных энцефалитов им. М.П. Чумакова
Russian Federation
Russian Federation
O. E. Ivanova
ФГБНУ «Институт полиомиелита и вирусных энцефалитов им. М.П. Чумакова»
Russian Federation
Russian Federation
E. G. Ipatova
ФГУП «Предприятие по производству бактерийных и вирусных препаратов Института полиомиелита и вирусных энцефалитов им. М.П. Чумакова
Russian Federation
Russian Federation
L. V. Gmyl
ФГУП «Предприятие по производству бактерийных и вирусных препаратов Института полиомиелита и вирусных энцефалитов им. М.П. Чумакова
Russian Federation
Russian Federation
A. A. Ishmuhametov
ФГУП «Предприятие по производству бактерийных и вирусных препаратов Института полиомиелита и вирусных энцефалитов им. М.П. Чумакова
Russian Federation
Russian Federation
References
1. Polio Eradication and Endgame Strategic Plan (2013 – 2018). Available at: http://www.polioeradication.org/Resourcelibrary/Strategyandwork.aspx.
2. Jiang S.D., Pye D., Cox J.C. Inactivation of poliovirus with β-propiolactone. Journal of Biological Standardization. 1986;14: 103 – 109.
3. Wilfried A.M., Bakker Yv., Thomassen E., van’t Oever A.G., Westdijk J., van Oijenet M.G.C.T. et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine. 2011; 29: 7188 – 7196.
4. Ivanov A.P., Kozlov V.G., Ivanova O.E., Kiktenko A.V. A method of quantitative determination of D-antigen of poliovirus types 1 – 3. Russian Patent Number 2535058, 14 December 2012 (In Russian).
5. Ivanov A.P., Kozlov V.G., Klebleeva T.D., Ivanova O.E., Kiktenko A.V. – The ELISA system based on specific class Y (IgY) antibodies from eff yolks for the quantitative determination of D-antigen in inactivated poliovirus vaccines. Voprosy Virusologii [Problems of Virology]. 2014; 59 (6): 39 – 42 (in Russian).
6. Expert committee on biological standardization, Geneva, 21 to 25 October 2013.
7. Ivanov A.P., Dragunsky E.M., Chumakov K.M.. 1,25-dihidroxyvitamin D3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. Journal of Infectious Diseases. 2006; 193: 598 – 600.
8. Simizu B., Abe S., Yamamoto H., Tano Y., Ota Y., Miyazawa M. et al. Development of inactivated poliovirus vaccine derived from Sabin strains. Biologicals. 2006; 34 (2): 151 – 154.
9. European Pharmacopoeia 7.0, 2010, 2.7.20: 225.
10. World Health Organization (WHO). Manual for the virological investigation of polio [WHO/EPI/GEN97.01]. Geneva: WHO; 1997.
11. Ivanov A.P., Dragunsky E.M., Ivanova O.E., Rezapkin G.V., Potapova S.G., Chumakov K.M. Poliovirus binding-inhibition ELISA for evaluation of immune response to oral poliovirus vaccine. Hum. Vaccines, 2005; 1: 102 – 105.
12. Recommendations to assure the quality, safety and efficacy of poliomyelitis vaccine (inactivated). Expert committee on biological standardization. Geneva, 13 to 17 October 2014.
Review
For citations:
Ivanov A.P., Klebleeva T.D., Ivanova O.E., Ipatova E.G., Gmyl L.V., Ishmuhametov A.A. Experimental Approaches to the Development of Inactivated Poliovirus Vaccine Based on Sabin Strains. Epidemiology and Vaccinal Prevention. 2016;15(4):59-64. (In Russ.) https://doi.org/10.31631/2073-3046-2016-15-4-59-64
Views:
827
Email this article 